Big picture - Why invest in Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Ltd Snapshot
Paradigm Biopharma Ltd (ASX:PAR) is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.
Graeme Kaufman BSc, MBA, has wide ranging experience across the biotechnology sector, spanning scientific, commercial and financial areas. His experience with CSL Limited, Australia’s largest biopharmaceutical company included responsibility for all of their manufacturing facilities, and the operation of an independent business division operating in the high technology medical device market. As CSL’s General Manager Finance, Mr Kaufman had global responsibility for finance, strategy development, human resources and information technology. Mr Kaufman has served as an executive director of ASX-listed Circadian Technologies and a non-executive director of Amrad Corporation, Bionomics Limited and Cellmid Limited. He held the role of Executive Vice President Corporate Finance with Mesoblast Limited until 2013 and is currently a non-executive director IDT Australia Limited.
Paul Rennie BSc, MBM, Grad Dip Commercial Law, MSTC, has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Paul’s experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their director of business development. Paul also led the commercialisation of Recaldent® a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. For the past 18 months Paul has worked full time at Paradigm BioPharmaceuticals Ltd.
Mr Christopher Fullerton
Christopher Fullerton, BEc, has extensive experience in investment, management and investment banking and is a qualified chartered accountant. He worked for 15 years in Hong Kong and South East Asia. He is an investor in listed equities and private equity and his current unlisted company directorships cover companies in the property investment and agriculture sectors. Mr Fullerton’s exposure to and experience in the fields of biotechnology and health care technology was gained through his non-executive chairmanships of Bionomics Limited (drug discovery), Cordlife Limited (cord blood banking) and Health Communication Network Pty Limited (healthcare software), and his non-executive directorship.
Mr John Gaffney
John Gaffney LL.M is a lawyer with over 30 years experience and has undertaken the AICD Company Directors qualification. He brings to the board a compliance and corporate governance background and is experienced in financial services compliance. John also has corporate and commercial experience having worked with a major national law firm as a senior lawyer and also practised as a Barrister at the Victorian Bar. Previously John has been a non executive director of a US based biotechnology company. He is currently a non – executive director of SelfWealth Ltd (ASX: SWF).
Last updated 14th December 2018
Level 2, 517 Flinders Lane
Melbourne VIC 3000
Phone: +61 3 9629 5566